Retinal oxygen metabolic rate (IRMRO
2) might be a key biomarker to investigate DR pathogenesis,
5 because complications of IRMRO
2 are present among different stages of DR and sensitive to development of DR. In early diabetes, oxidative stress in the retina can influence retinal cellular oxygen metabolism,
6 thus potentially triggering variations of IRMRO
2. In DR, retinal microvasculature abnormalities,
7 including capillary wall thickening
8 and vessel tortuosity,
9 may affect retinal perfusion and oxygen delivery, changing the IRMRO
2.
10 In addition, the retina is nourished by both the retinal and choroidal vascular systems. Both early diabetes and DR can influence the perfusion of choroidal circulation,
11 which may further affect retinal oxygen metabolism. Therefore, quantification of IRMRO
2 is important to understand DR; however, IRMRO
2 studies are difficult. First, it is challenging to investigate IRMRO
2 on patients with early DR due to the difficulty in defining DR stages among diabetes patients. Second, DR is a dynamic disease; IRMRO
2 can change along the progress of DR. Thus, the imaging time point could influence the measured results of IRMRO
2. Third, IRMRO
2 requires measuring both retinal blood flow and oxygen saturation (sO
2) simultaneously and precisely.
12 The lack of an accurate, noninvasive detection modality will bias IRMRO
2 measurements. For instance, measuring retinal sO
2 is difficult with multi-wavelength fundus photography
13 because of the signal degradation due to light scattering. The recently developed multi-wavelength photoacoustic ophthalmoscope (PAOM) shows promise in generating an accurate retinal sO
2 reading
12; however, physical contact between the acoustic transducer and the eyeball in PAOM will be inconvenient and limit its applications. The aforementioned challenges, including unclear definitions of DR stages, inconsistent imaging time points, and unreliable imaging tools, have prevented investigation of IRMRO
2 in DR.